Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Benefits of MRD use in ALL

Torsten Haferlach • 4 May 2018
ESH AL 2018
Acute Lymphoblastic Leukemia Leukemia

In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, comments on the benefits of the use of measurable residual disease (MRD) to inform treatment decisions rather than having to rely on morphology assessments. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Torsten Haferlach

3:33
The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
Torsten Haferlach • 9 Dec 2023
1:52
Implementing AI in hematology and the challenges this will overcome
Torsten Haferlach • 9 Dec 2023
2:57
Why do we need AI in the hematology clinic?
Torsten Haferlach • 9 Dec 2023
1:53
Role of NGS in acute leukemias
Torsten Haferlach • 17 Sep 2020

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals